https://scholars.lib.ntu.edu.tw/handle/123456789/487345
Title: | Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial | Authors: | CHIA-CHI LIN CHIH-HUNG HSU Hour T.-C. ANN-LII CHENG CHAO-YUAN HUANG KUO-HOW HUANG Chen J. YEONG-SHIAU PU |
Issue Date: | 2007 | Journal Volume: | 25 | Journal Issue: | 3 | Start page/Pages: | 207-213 | Source: | Urologic Oncology: Seminars and Original Investigations | Abstract: | Purpose: Paclitaxel and 5-fluorouracil have been used to treat hormone-refractory prostate cancer with some success. In vitro data suggest that the combined cytotoxicity may be sequence dependent. Thus, we explored the combined effects of the 2 agents, both in vitro and in vivo. Patients and Methods: The combined cytotoxicity of paclitaxel and 5-fluorouracil, and the possible schedule dependence were studied in vitro using PC-3 and DU145 cells and the microculture tetrazolium assay. There were 23 patients with hormone-refractory prostate cancer treated with the regimen T-HDFL: paclitaxel 90 mg/m2 intravenously 1 hour on days 1 and 8; 5-fluorouracil 2000 mg/m2; and leucovorin 300 mg/m2 intravenous 24-hour infusion on days 2 and 9, which repeated every 21 days. The allowed percentage of bone marrow irradiation was 50%. Results: Significant synergistic cytotoxicity was seen only when paclitaxel was given 24 hours before 5-fluorouracil. With the T-HDFL regimen, 11 (52%) of the 21 evaluable patients had ?50% reduction of prostate-specific antigen, lasting for 6 weeks. Of the 7 patients with measurable disease, 2 had a partial response. Median overall survival was 14.1 months. Grade III/IV leukopenia occurred in 2 patients. There was no treatment-related death. Toxicities were well tolerated. Conclusions: The combined cytotoxicity of paclitaxel and 5-fluorouracil is schedule dependent. It is feasible to administer weekly paclitaxel and high-dose 5-fluorouracil infusions in patients with hormone-refractory prostate cancer. Our findings may serve as an important rationale for future trial design. ? 2007 Elsevier Inc. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247618891&doi=10.1016%2fj.urolonc.2006.06.002&partnerID=40&md5=eb8ce55d30310a86764bd450b76489e9 https://scholars.lib.ntu.edu.tw/handle/123456789/487345 |
ISSN: | 1078-1439 | DOI: | 10.1016/j.urolonc.2006.06.002 | SDG/Keyword: | analgesic agent; betamethasone; fluorouracil; folinic acid; paclitaxel; tetrazolium; adult; aged; alopecia; anemia; article; bone marrow; bone metastasis; cancer pain; cancer survival; cell culture; clinical trial; controlled clinical trial; controlled study; cytotoxicity; demography; diarrhea; drug antagonism; drug dose reduction; drug exposure; drug potentiation; drug tolerability; drug withdrawal; febrile neutropenia; hand foot syndrome; human; human cell; infection; irradiation; leukopenia; liver metastasis; liver toxicity; lymph node metastasis; male; multiple cycle treatment; nausea; nephrotoxicity; neurotoxicity; phase 2 clinical trial; priority journal; prostate cancer; stomatitis; thrombocytopenia; treatment response; vomiting; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.